IL-33/ST2 Expression Profiling for Prediabetes Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and preventing the progression from prediabetes to Type II Diabetes are inadequate, as they lack sensitivity and specificity, often resulting in delayed detection and intervention.
Innovation Solution
A method involving the analysis of IL-33/ST2 expression profiles in adipose tissue to identify individuals at risk of developing Type II Diabetes, with interventions such as pharmaceutical compositions, dietary supplements, modified diets, or exercise regimes based on specific gene expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for detecting Type II Diabetes, then the diagnosis can be made, but the detection is delayed and lacks sensitivity and specificity
Solution Approach 1:
The patent applies preliminary action by detecting IL-33/ST2 expression profiles in adipose tissue before the full development of Type II Diabetes. This allows identification of individuals in the prediabetes stage or at high risk, enabling early intervention before significant glycemic abnormalities occur, thus preventing detection delay and improving early diagnosis capability
Solution Approach 2:
The patent uses IL-33/ST2 expression profile as an intermediary biomarker to detect early signs of diabetes risk. Instead of relying on traditional glucose-based diagnostics that only show abnormalities after diabetes develops, the IL-33/ST2 profile serves as an early warning signal that precedes clinical diabetes, improving both sensitivity and timing of detection
2Reliability
If traditional diagnostic methods are used, then the diagnosis process is simple, but the ability to predict and prevent progression from prediabetes is insufficient
Solution Approach 1:
The patent replaces traditional mechanical/chemical diagnostic methods (glucose tolerance tests, HbA1c measurements) with a molecular biology-based approach using gene expression analysis. By substituting conventional diagnostics with IL-33/ST2 expression profiling, the method achieves superior predictive reliability for diabetes progression while accepting increased analytical complexity
Solution Approach 2:
The patent changes the diagnostic parameter from glucose metabolism markers to gene expression markers (IL-33 and ST2). This parameter change enables detection of early molecular changes in adipose tissue that precede clinical diabetes, significantly improving prediction capability despite requiring more complex molecular analysis techniques
Data Source
AI summary
The method for preventing progression to Type II Diabetes includes determining whether a subject possesses a risk variant expression profile demonstrating dysregulation of the IL-33/ST2 axis, and providing an intervention to prevent progression to Type II Diabetes and/or to reverse prediabetes, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with Type II Diabetes or prediabetes, such as heart disease, stroke, or obesity. The pharmaceutical compound may be one or more pharmaceuticals capable of reducing circulating cholesterol, reducing blood glucose levels, reducing blood pressure, or a combination thereof.